Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus etoposide and carboplatin first-line for extensive-stage small cell lung cancer
ChiCTR2000037758Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, etoposide and carboplatin in small cell lung cancer (SCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
anlotinibetoposidecarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000037758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037758.